MELBOURNE CONVENTION AND EXHIBITION CENTRE - March 22nd - 24t h 2018 - www.ausmnd.com.au - Australasian MND ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
www.ausmnd.com.au
M ELBOURNE CONVENTION AND
EXHIBITION CENTRE
M ar ch 22n d - 24t h 2018
2018 AUSTRALASIAN M ND SYM POSIUM
TABLE OF CONTENTS
W ELCOM E 3
ABOUT THE SYM POSIUM - INVITED SPEAKERS 4
GENERAL SYM POSIUM INFORM ATION 5
REGISTRATION 6
CALL FOR ABSTRACTS - BIOM EDICAL & CLINICAL STREAM S 7
ABSTRACTS FAQs 11
PRIZES - POSTER PRIZES 12
BIOM EDICAL STREAM KEYNOTE PRESENTATIONS 14
CLINICAL STREAM KEYNOTE PRESENTATIONS 15
PROGRAM - DRAFT 16
DESTINATION - M ELBOURNE 19
SPONSORSHIP AND TRADE EXHIBITION 20
2
JOIN US IN M ELBOURNE FOR THE INAUGURAL FIGHTM ND
AUSTRALASIAN M OTOR NEURONE DISEASE SYM POSIUM
M ar ch 22n d - 24t h 2018
CONNECT. COLLABORATE. EDUCATE. INSPIRE
FightMND and the Organising Don't miss this opportunity to attend
Committee takes great pleasure in and/or present on your research or
inviting you to the inaugural 2018 MND care area of speciality at this
FightMND Australasian Motor national MND meeting.
Neurone Disease Symposium. The theme of this inaugural symposium
The symposium will provide a major is to "Connect , Collaborat e, Educat e,
forum for researchers, clinicians, and and Inspire", with the aims of
patients to connect, exchange ideas, invigorating and growing the local
and discuss clinical and research MND research community, inspiring
issues related to scientific research innovation , and helping to foster new
into finding effective treatments for local and international collaborations
this devastating disease, and between our researchers, clinicians,
improving the care of those currently and scientists.
fighting the disease.
3
ABOUT THE SYM POSIUM
The inaugural Fight MND Aust ralasian MND
Symposium will feat ure a dynamic t hree day
program incorporat ing a variet y of keynot e
present at ions from invit ed local and overseas
MND expert researchers and clinicians, oral
and post er present at ions, t rade
demonst rat ions, and net working opport unit ies
KEYNOTE SPEAKERS
Professor Kevin Talbot Professor Dom Rowe
Oxford University, UK Macquarie University, Australia
HEADER
Professor Jeremy Shefner Professor Robert Henderson
Barrow Neurological Institute, USA University of Queensland, Australia
Professor Ammar Al-Chalabi Professor Naomi W ray
Kings College, London University of Queensland Australia
Professor Don Cleveland Assoc. Professor Paul Talman
University of California, USA Barwon Health, Australia
Professor Kevin Eggan Professor Samar Aoun
Harvard University, USA Curtin University, Australia
Professor St anley Appel Professor Julian Gold
Weill Cornell Medical College, USA Albion Institute, Australia
Professor Michael Benat ar Karol Connors (Physiot herapist )
University of Miami, USA Calvary Healthcare Bethlehem, Australia
Professor Robert Bowser Sarah Solomon (Occupat ional Therapist )
Barrow Neurological Institute, USA Calvary Healthcare Bethlehem, Australia
Dr Lucie Bruijn Charlene Cullen (Speech Therapist )
ALSA, USA LinkAT
Professor Clive Svendsen Renae Knight (Occupat ional Therapist )
Cedars Sinai, USA Metro Health South QLD, Australia
Professor Luis Barbeit o St ephanie W illiams (Occupat ional Therapist )
Institut Pasteur de Montvideo, Uruguay Calvary Healthcare Bethlehem, Australia
Professor Mat t hew Kiernan Rachael Russell (Occupat ional Therapist )
University of Sydney, Australia Calvary Healthcare Bethlehem, Australia
Professor St even Vucic
University of Sydney, Australia
4
SYM POSIUM
VENUE
The inaugural 2018
FightMND Australasian
Motor Neurone Disease
Symposium will be held at
the Melbourne Convention
and Exhibition Centre.
Recognised as Australasia?s
Leading Meetings and
Conference Centre from
2012 ? 2016 by the
prestigious World Travel
Awards, Melbourne
Convention and Exhibition
Centre (MCEC) connects us
with everything we need for
a successful event ?
incredible spaces, leading
technology, award-winning
food and the expertise to
bring it all together.
M ELBOURNE , AUSTRALIA
DELEGATES
It is anticipated that SYM POSIUM THEM ES
between 200 to 500 BIOMEDICAL STREAM
delegates from Australia,
New Zealand, and abroad - Genetics and genomics
will attend the 2018 - Big data analysis and management
Australasian MND - Biomarkers
Symposium from the - Pathophysiology / Disease mechanisms
following professions and - Disease models
backgrounds: - Neuroinflammation
- Stem Cells
- Clinical & laboratory - Preclinical drug development
MND researchers
- Neurologists CLINICAL STREAM
- General Practitioners - Disease phenotypes and classification
- Palliative care - Disease registries
physicians - Clinical Trials and trial design
- Allied Health - Clinical management and care
professionals - Assistive Technology
- Nursing staff - Cognitive change and assessment
- MND patients - Respiratory management
- Carers - Nutritional management
- Palliative and end of life care
- Care giver support 5
JOIN US IN M ELBOURNE FOR THE INAUGURAL FIGHTM ND
AUSTRALASIAN M OTOR NEURONE DISEASE SYM POSIUM
M ar ch 22n d - 24t h 2018
REGISTRATION
Further information & online registration is available online at ht t ps://ausmnd.com.au/regist er
FEES: All pricesare listed in AUD
STUDENT - EARLY BIRD (UNTIL NOVEM BER 1ST 2017) $150 +GST
STUDENT - STANDARD REGISTRATION (FROM 2ND NOVEM BER 2017 TO $220 +GST
JANUARY 31ST 2018)
NON-STUDENT - EARLY BIRD (UNTIL NOVEM BER 1ST 2017) $250 +GST
NON-STUDENT - STANDARD REGISTRATION (FROM 2ND NOVEM BER 2017 TO $320 +GST
JANUARY 31ST 2018)
M ND PATIENT - EARLY BIRD (UNTIL NOVEM BER 1ST 2017) $100 +GST
M ND PATIENT - STANDARD REGISTRATION (FROM 2ND NOVEM BER 2017 TO $150 +GST
JANUARY 31ST 2018)
LATE REGISTRATION (FROM 1ST FEBRUARY 2018 TO $350 +GST
28TH FEBRUARY 2018)
ONSITE REGISTRATION (FROM M ARCH 1ST 2018) $450 +GST
SINGLE DAY REGISTRATION $150 +GST
M ELBOURNE , AUSTRALIA 6
CALL FOR ABSTRACTS
BIOM EDICAL & CLINICAL STREAM S
SUMMARY OF CONDITIONS OF ACCEPTANCE HEADER
Melbourne, Aust ralia
March 22nd - 24t h 2018
ABSTRACTS - BIOM EDICAL STREAM
Abstracts are now being called for oral and poster presentations for the Biomedical
St ream of the AMNDS 2018 meeting. The organising committee encourages
submissions which fall within the following themes:
- Genetics and genomics
- Big data analysis and management
- Biomarkers
- Pathophysiology / Disease mechanisms (broad category)
- Disease models
- Neuroinflammation
- Stem Cells
- Preclinical drug development
ABSTRACTS - CLINICAL STREAM
Abstracts are now being called for oral and poster presentations for the Clinical
St ream of the AMNDS 2018 meeting. The organising committee encourages
submissions which fall within the following themes:
- Disease phenotypes and classification
- Disease registries
- Clinical trials and trial design
- Clinical management of MND patients (broad category)
- Assistive technology
- Cognitive change and assessment
- Respiratory management
- Nutritional management
- Palliative and end of life care
- Carer support
PRESENTATION FORM ATS
Oral platform presentations are 20 minutes in total length and speakers should
allow for a 15 minute presentation followed by a 5 minute question period.
Posters should be paper size A0, ( 841 x 1189mm). Please ensure that the longest
side of your poster is its height, sometimes known as ?portrait?orientation. In other
words 841mm wide (horizontally) and 1189mm metre high (vertically).
7
2018 AUSTRALASIAN M ND SYM POSIUM
ABSTRACT SUBM ISSION GUIDELINES
- Submission of your abstract acknowledges consent to publication of the
abstract in the Symposium proceedings, Symposium app, and the Symposium
website.
- All abstracts must be submitted online.
To submit your abstract online, head to
ht t ps://app.oxfordabst ract s.com/st ages/ 198/submission
- Abstracts will be submitted under the ?oral preferred?or ?post er preferred?
categories and while every effort will be made to accommodate these
preferences the organising committee cannot make any guarantees.
- Authors accepting the offer of a poster presentation must ensure that their
poster is on display at the symposium venue at the designated time. The
corresponding author will be notified of the time slot and it must be abided
by.
- Abstracts may be submitted even if previously presented at a
national/international meeting.
- Multiple abstract submissions per person are allowed, but registrants can
only give a maximum of two (2) oral presentations during the entire
Symposium. There is no limit on the number of poster presentations per
registrant.
- Abstracts should be submitted by the corresponding author of the abstract.
The corresponding author is the ONLY person that will receive email
correspondence from us.
- The email address of the corresponding author will be published with any
accepted abstracts.
- The present ing aut hor (for eit her an oral or post er present at ion) will be
required t o regist er for t he Symposium before submit t ing his/ her abst ract
in order to ensure their abstract(s) is included in the final program. Formal
acceptance of an abstract is conditional upon payment of the registration
fee, and abstracts will not be considered for inclusion unless the presenting
author has registered to attend the Symposium.
- Please ensure you have the correct permissions to submit your abstract (eg
from collaborators or funders).
- All abstracts should be submitted online via the submission portal
- Abstracts must be in English, and be no longer than 500 words (excluding
titles and references) and limited to one page only.
- Tables and figures CAN NOT be included
8
2018 AUSTRALASIAN M ND SYM POSIUM
ABSTRACT SUBM ISSION GUIDELINES CONTINUED
- Please only use standard abbreviations or define them in full.
- SI units should be used
- For multiple affiliations use numbered superscripts.
- Paragraphs should be separated by an empty line, please do not indent the first
line of a paragraph
- Please not e: Accuracy is the responsibility of the author, please ensure you have
proof read your document carefully. Whilst every effort will be made to ensure
the reproduction of symbols, accuracy of symbols cannot be guaranteed in the
reproduction.
- Abst ract Tit le: Please write the title in sentence case (capitalising only the first
word and proper nouns), do not use quotation marks. The title should be as brief
as possible but long enough to indicate clearly the nature of the study. The title
is not included in 500 word limit.
- Abstracts that merely state the results that will be presented will be subject to
rejection.
- Do not include aut hor names in t he t it le or body of your abst ract because a
?blind?reviewing process will be used. You will be asked to enter the names online
during the submission process.
- All abstracts are subject to review by the Program Committee and acceptance
into the program is not guaranteed.
- Avoid starting abstracts with very basic descriptions of ALS/MND e.g. ?ALS/MND
is an adult-onset, rapidly progressive neurodegenerative disease?as an opening
sentence (this is an MND conference so this knowledge is assumed)
- Please ensure that the text of your abstract is spellchecked before it is
submitted.
- Conflict of Int erest St at ement : If the research described in the abstract was
supported by a commercial company you must indicate the company's role in
analysing the data or preparing the abstract. You will be asked to declare any
conflicts during the submission process.
Abstract submissions are now open
Abst ract submissions close: 6.00pm December 18th 2017
Abst ract present at ion announcement s: January 19th 2019
To submit an abst ract , t he present ing aut hor needs t o regist er in full t o at t end t he
symposium.
To register click here
9
2018 AUSTRALASIAN M ND SYM POSIUM
ABSTRACT SUBM ISSION GUIDELINES CONTINUED
For oral or poster presentations where scientific / experimental results data is to be
presented, the Committee suggests that where applicable the abstract follow the
format outlined below.
- Aim
State concisely why the study was conducted
- Case St udies
State the nature of the case study which you will be presenting
- Met hod
Indicate the locale, sample number (n), principal test(s) performed, and the types of
statistical analysis employed
- Result
Confirm or refute the hypothesis, supported by statistics if appropriate (p values).
- Conclusion
State the effect of the study on future research, patient management, or the
understanding of basic disease processes
- References
References in the text should be cited as numbers in brackets. References should also
be listed in order of citation at the end of the text. All authors should be quoted for
papers with up to three authors; for papers with more than three authors the first
three should be quoted followed by ?et al?.Incomplete references will be removed at
the editor?s discretion.
For oral or poster presentations where more general topics (e.g. The role of non-invasive
ventilation in MND) are to be presented, the Committee suggests that where
applicable the abstract follow the format outlined below.
- Aim
State concisely the purpose of your presentation
- Audience
Indicate the target audience for your presentation
- Key messages
Outline the key messages you are aiming to cover in your oral and/or poster
presentation
- Conclusion
State the impact on future patient management or research
- References
References in the text should be cited as numbers in brackets. References should also
be listed in order of citation at the end of the text. All authors should be quoted for
papers with up to three authors; for papers with more than three authors the first
three should be quoted followed by ?et al?.Incomplete references will be removed at
the editor?s discretion.
102018 AUSTRALASIAN M ND SYM POSIUM
ABSTRACTS - FREQUENTLY ASKED QUESTIONS
How do I submit my abst ract ?
Submit your abstract online through our submission portal at
ht t ps://app.oxfordabst ract s.com/st ages/ 198/submission.
Formal acceptance of an abstract is conditional upon payment of the registration fee, and
abstracts will not be considered for inclusion unless the presenting author has registered
to attend the Symposium. To submit your abstract, register to attend the Symposium -
head to the registration page at ht t ps://ausmnd.com.au/regist er.
W hat is t he abst ract submission deadline?
The closing date for abstract submission is December 18th 2017.
Do you accept encore abst ract s?
Yes, you can still submit an abstract if the material has been presented elsewhere however
you must disclose this information during the submission process. A preference will be given
to abstracts for material that has not been presented before.
Do you accept lat e breaking abst ract s?
No, there is no late breaking abstract submission.
W hen will I know if my abst ract has been accept ed?
The abstracts will be subject to a blind review process after the submission date closes and
then review by the organising committee. We anticipate notifying authors of acceptance /
rejection in mid January 2018.
M y abst ract has been accept ed but I can not at t end, what do I do?
The presentation can be delivered by another named author, this author must have been
included on the original abstract submission. Please email research@fight mnd.org.au to
advise of any change of presenter.
I want t o wit hdraw my abst ract
If you wish to withdraw an abstract please contact the organising committee by email as
soon as possible Please email research@fight mnd.org.au .
I submit t ed an abst ract but t he dat a has changed or is not available. W hat do I do?
Please email research@fight mnd.org.au to advise if you will need to withdraw or update
your abstract.
W hen will t he abst ract s be published?
Abstracts will be made available electronically, via the Symposium website, and the app,
shortly before the Symposium. A book of abstracts will also be available at the symposium
for all paid registrants.
11PRIZES - POSTERS HEADER
BIOM EDICAL & CLINICAL STREAM S
Prizes will be awarded for the best poster in both the biomedical and clinical streams.
Value:
The value of each poster prize is $1,000 AUD
Eligibilit y:
The poster prizes are open to the following:
- Biomedical st ream: PhD students OR early career MND/ALS researchers ( researchers
awarded their PhD within the last 5 years)
- Clinical st ream: as per Biomedical stream above but also including medical and allied
health professionals working with MND/ALS patients.
The present ing aut hor will be required t o regist er for t he Symposium before submit t ing
his/ her abst ract for considerat ion of a post prize award.
To be eligible to receive one of the poster prizes, the presenting author must select the box and
confirm their eligibility (as per above) within the abstract submission portal process, to indicate
that they wish to be considered for the prize.
Indicating that you are eligible for a poster prize will not affect your likelihood of being chosen
for an oral communication if you have selected the ?oral preferred?option in the abstract
submission process.
12PRIZES - POSTERS
HEADER
BIOM EDICAL & CLINICAL STREAM S
Scoring:
The initial stage of judging will be based on the abstracts, as submitted by the abstract
submission deadline. Final judging of shortlisted posters will take place at the symposium and
all posters will be scored using the following criteria:
Poster Design:
- Organisat ion and clarit y: Is the poster content organised in a logical manner, such that
experimental problem, approach and results are easily understood?
- Layout & visual impact : Is the poster layout/look/feel well done? Is there use of
appropriate font sizes, readable graphics, suitable colors, pictures etc? ?
Poster Content:
- Mot ivat ion/ Background: Does the poster and the presenting author present sufficient
context for the reader to understand the purpose and originality of the experiment as
well as the background and motivation for performing the experiment or presenting the
case study or topic presentation?
- Met hod: Does the poster present sufficient data on the experimental methods used for
the reader to understand and judge the quality of the approach?
- Result s & Discussion: Does the poster demonstrate an understanding of the
significance of results presented?Presenter should provide appropriate statistics as
appropriate.
- Conclusions & scient ific cont ribut ion: Does the poster and the presening author
present sufficient information and data to support the conclusion(s) of the poster? Does
the results of the experiment or case study presented represent an important advance
towards MND research or patient care and the understanding of the cause(s), disease
mechanisms, potential treatments, and advances to improve care of MND patients?
The present er must be available at an allocat ed t ime t o answer quest ions from t he judges
at t he conference.
13BIOM EDICAL STREAM PRESENTATIONS
(Subject to change)
Professor Matthew Kiernan
HEADER
MND in Australia - where we've been, where we are, and where we are going
Professor Stanley Appel
Suppressing neuroinflammation: cell-based therapy for MND/ALS
Professor Kevin Talbot
Modelling early phase pathogenesis in amyotrophic lateral sclerosis
Professor Don Cleveland
Gene silencing therapy for ALS and beyond
Professor Robert Bowser
Discovery and use of biomarkers in ALS
Professor Luis Barbeito
Pharmacological inhibition of CSF1R and C-kit reveals new pathogenic mechanisms in ALS
Professor Naomi Wray
Making sense of big data in in the age of - Omics MND/ALS research
Professor Steve Vucic
A Phase II double-blind, placebo controlled clinical trial of Tecfidera in ALS
Professor Dom Rowe
A Phase I Australian clinical trial of Copper-ATSM in MND/ALS patients
Professor Rob Henderson
A Phase I Australian clinical trial of an immunotherapeutic drug in MND/ALS
Professor Julian Gold
Lighthouse Trial: A Phase II clinical trial of Triumeq in MND/ALS patients
Professor Jeremy Shefner Professor Clive Svendsen
Topic TBC Topic TBC
Professor Kevin Eggan Professor Michael Benatar
Topic TBC Topic TBC
Professor Ammar Al-Chalabi Dr Lucie Bruijn
Topic TBC Topic TBC
Professor Kevin Eggan
Topic TBC
14CLINICAL STREAM PRESENTATIONS
(Subject to change)
Professor Matthew Kiernan
HEADER
MND in Australia - where we've been, where we are, and where we are going
Sarah Solomon
The role of the OT in the lives of people living with MND - navigating an ever changing
level of function
Stephanie Williams
An update on managing comfort and pressure care for people with MND - a holistic
approach
Karol Connors
Assistive technology usage by people living with MND: who needs what and when?
Rachael Russell
Clinical reasoning for the implementation of eye gaze technology for people with MND
Charlene Cullen
Hold on to your voice: options for voice banking and message banking for people with
MND
Professor Samar Aoun
The palliative approach to caring for MND: From diagnosis to bereavement
Andrew Denton
Voluntary Assisted Dying Laws - Let's discuss
Professor Jeremy Shefner
Global MND/ALS Clinical Trials Update - what have we learned and how can we improve
clinical trial design
Professor Ammar Al-Chalabi
What causes MND? Why me?
Professor Kevin Talbot
Why havent we found a cure yet?
Professor Kevin Eggan
Stem cells in MND research & treatment - an update
15TIM E THURSDAY 22ND MARCH 2018 TIM E THURSDAY 22ND MARCH 2018
BIOMEDICAL STREAM CLINICAL STREAM
7.30 AM Regist rat ion desk opens 7.30 AM Regist rat ion desk opens
DRAFT PROGRAM : THURSDAY 22ND M ARCH 2018
Coffee, tea, and refreshments Coffee, tea, and refreshments
8.30 AM Open and Welcome - joint session 8.30 AM Open and Welcome - joint session
8.45 AM Keynot e Present at ion - joint session 8.45 AM
HEADER
Keynot e Present at ion - joint session
Professor Matthew Kiernan Professor Matthew Kiernan
MND in Australia - where we've been, where we are, and where we are going MND in Australia - where we've been, where we are, and where we are going
9.45 AM Morning t ea break, Trade Exhibit ion 9.45 AM Morning t ea break, Trade Exhibit ion
RESEARCH SESSION 1A: Neuroinflammation and Glia / Disease Mechanisms CLINICAL SESSION 1B: Clinical Management of MND patients A
10.15 AM Keynot e Present at ion - 35 mins 10.15 AM Keynot e Present at ion - 35 mins
Professor Stanley Appel Sarah Solomon
Suppressing Neuroinflammation - Cell-based therapy for MND/ALS The role of the OT in the lives of people living with MND - navigating an ever changing
level of function
10.50 AM Keynot e Present at ion - 35 mins
10.50 AM Keynot e Present at ion - 35 mins
Professor LouisBarbeito
Stephanie Williams
Pharmacological inhibition of CSF1R and C-kit reveals new pathogenic mechanisms
in inherited ALS An update on managing comfort and pressure care for people with MND - a holistic
approach
11.25 AM Plat form Present at ions x 2 20 min each (incl. 5 minute question time)
11.25 AM Plat form Present at ions x 2 20 min each (incl. 5 minute question time)
12.05PM Lunch break, Trade Exhibit ion
12.05 PM Lunch break, Trade Exhibit ion
RESEARCH SESSION 2A: Disease Mechanisms / Genetics/ Genomics / Big Data
CLINICAL SESSION 2B: Assistive Technology & Equipment
1.10 PM Keynot e Present at ion - 35 mins
1.10 PM Keynot e Present at ion - 35 mins
Professor Kevin Talbot Karol Connors
Modelling early phase pathogenesis in amyotrophic lateral sclerosis Assistive technology usage by people living with MND: who needs what and when?
1.45 PM Keynot e Present at ion - 35 mins 1.45PM Keynot e Present at ion - 35 mins
Professor Don Cleveland Rachael Russell
Gene silencing therapy for ALS and beyond Clinical reasoning for the implementation of eye gaze technology for people with MND
2.20 PM Plat form Present at ions x 4 20 min each (incl. 5 minute question time) 2.20 PM Plat form Present at ions x 4 20 min each (incl. 5 minute question time)
3.40 PM Aft ernoon t ea break, Trade Exhibit ion 3.40 PM Aft ernoon t ea break, Trade Exhibit ion
(Subject to change)
4.15 PM Keynot e Present at ion - 35 mins 4.15 PM Keynot e Present at ion - 35 mins
Professor Naomi Wray Charlene Cullen
Hold on to your voice: options for voice banking and message banking for people with
Making sense of big data in the age of -Omics MND/ALS research
MND
5.00 PM - 6.30PM POSTER SESSION A 5.00 PM - 6.30PM POSTER SESSION ATIM E FRIDAY 23RD MARCH 2018 TIM E FRIDAY 23RD MARCH 2018
BIOMEDICAL STREAM CLINICAL STREAM
8.30 AM Regist rat ion desk opens 8.30 AM Regist rat ion desk opens
DRAFT PROGRAM : FRIDAY 23RD
Coffee, tea, and refreshments Coffee, tea, and refreshments
9:00 AM Keynot e Present at ion - joint session 9:00 AM Keynot e Present at ion - joint session
Andrew Denton HEADER
Andrew Denton
Voluntary Assisted Dying Laws - Let's discuss
Voluntary Assisted Dying Laws - Let's discuss
9.45 AM Morning t ea break, Trade Exhibit ion
9.45 AM Morning t ea break, Trade Exhibit ion
RESEARCH SESSION 3A: Preclinical Drug Development CLINICAL SESSION 3B: Clinical Management of MND patients B
10.15 AM Keynot e Present at ion - 35 mins 10.15 AM Keynot e Present at ion - 35 mins
10.50 AM Plat form Present at ions x 4 20 min each (incl. 5 minute question time) 10:50 AM Plat form Present at ions x 4 20 min each (incl. 5 minute question time)
12.10 PM Lunch break, Trade Exhibit ion
12.10 PM Lunch break, Trade Exhibit ion
RESEARCH SESSION 4A: Disease Models / Biomarkers / Stem Cells
CLINICAL SESSION 4B: Palliative and End of Life Care . Carer support
1.10 PM Keynot e Present at ion - 35 mins
1.10 PM Keynot e Present at ion - 35 mins
Professor Michael Benatar
Professor Samar Aoun
M ARCH 2018
The palliative approach to caring for MND: From diagnosis to bereavement
1.45 PM Plat form Present at ions x 6 20 min each (incl. 5 minute question time)
1.45 PM Plat form Present at ions x 6 20 min each (incl. 5 minute question time)
3.45 PM Aft ernoon t ea break, Trade Exhibit ion
3.45 PM Aft ernoon t ea break, Trade Exhibit ion
4.15 PM Keynot e Present at ion - 35 mins 4.15 PM Keynot e Present at ion - 35 mins
Professor Kevin Eggan
(Subject to change)
5.00 PM - 6.30PM POSTER SESSION B
5.00 PM - 6.30PM POSTER SESSION B
7:00 PM NETW ORKING COCKTAIL FUNCTION 7:00 PM NETW ORKING COCKTAIL FUNCTIONDRAFT PROGRAM :
SATURDAY 24TH M ARCH 2018 COM BINED PROGRAM
CLINICAL TRIALS UPDATE & ASK THE EXPERTS (Subject to change)
TIM E SATURDAY 24TH MARCH 2018
HEADER
JOINT SESSION
8.30 AM Regist rat ion desk opens
Coffee, tea, and refreshments
9:00 AM Keynot e Present at ion
Assoc. Professor Paul Talman
The Australian Motor Neurone Disease Registry - an update
9.45 AM Morning t ea break, Trade Exhibit ion
JOINT SESSION: Clinical Trials and trial design update
10.15 AM Keynot e Present at ion
Professor Jeremy Shefner
Global MND/ALS Clinical Trials Update - what have we learned and how can we improve clinical trial design
11.15 AM Current and Upcoming Aust ralian MND Clinical Trials Updat e
Professor Steve Vucic
Professor Julian Gold
Professor Dominic Rowe
Professor Rob Henderson
12.55 PM Lunch break, Trade Exhibit ion
2.00PM POSTER AWARDS
JOINT SESSION: Ask the Experts
2:20 PM Updat es for t he MND Communit y
Professor Ammar Al-Chalabi - W hat causes MND? W hy me?
Professor Kevin Talbot - W hy havent we found a cure yet ?
Professor Kevin Eggan - St em cells in MND research & t reat ment - an updat e
3:20 PM PANEL Q & A - ASK THE EXPERTS
4:05 PM Thank you and closeM ELBOURNE
JOIN US FOR THE INAUGURAL FIGHTM ND AUSTRALASIAN
M OTOR NEURONE DISEASE SYM POSIUM
Melbourne is a city that knows how to live and has been voted the "World's most livable city" for the
last seven years in a row from 2011 to 2017. Choose from high-end cuisine to basement rock music
gigs, plays, festivals and blockbuster sporting events ? all happening across a city full of parks,
gardens and historic architecture. Dive in to discover the distinct fortes and flavours of Melbourne
destinations.
Spend some time in the city centre and you?ll discover it?s neatly divided into little pockets for you to
explore. Find art, bars and restaurants up and down in the laneways, retail therapy for any budget in
Bourke and Collins streets, and creative outlets on show in Flinders Quarter. St Kilda Road means
galleries and gardens, while neighbouring Yarra Precinct and Docklands deliver waterside views by
the boatload.
Just a tram ride away, the eclectic neighbourhoods on the city fringe offer endless possibilities. Take
your fixie for a spin in the tooth-achingly cool northern suburbs Collingwood, Fitzroy, Brunswick and
Northcote. Flex your plastic in retail meccas South Yarra, Prahran and Toorak. Take your beach towel
(or yacht) to bayside St Kilda, Port Melbourne and South Melbourne, and go west for more fabulous
food and beaches.
Find out more about what Melbourne has to offer :
ht t p:// www.visit melbourne.com/ Regions/ Melbourne
619JOIN US IN M ELBOURNE FOR THE INAUGURAL FIGHTM ND
AUSTRALASIAN M OTOR NEURONE DISEASE SYM POSIUM
M ar ch 22n d - 24t h 2018
SPONSORSHIP AND TRADE EXHIBITION
Don't miss this opportunity to showcase your organisation at this national MND
meeting.
Becoming a part of our symposium helps build your brand, strengthens the MND
research and patient care industry, creates unique relationships, provides networking
opportunities, and allows you to demonstrate your commitment to improving the lives
of MND patients.
DOW NLOAD SPONSORSHIP AND TRADE EXHIBITION PROSPECTUS
M ELBOURNE , AUSTRALIA 202018 AUSTRALASIAN M ND SYM POSIUM
REGISTERED AUSTRALIAN CHARITY
ACNC: 62 740 350 704
PO BOX 23390, DOCKLANDS, VIC, 8012
WWW.FIGHTMND.ORG.AU
RESEARCH@FIGHTMND.ORG.AUYou can also read
